Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance

Sixuan Zhao, Na He, Yahui Zhang, Chuhui Wang, Suodi Zhai, Chao ZhangAntibiotics 2021 · DOI

TL;DR

This study developed a population pharmacokinetic model for vancomycin in Chinese patients, specifically addressing Augmented Renal Clearance (ARC). By identifying key factors influencing vancomycin levels, they propose optimized dosing regimens to improve treatment efficacy and safety, particularly for patients with higher kidney function.

What Problem Does This Paper Address?

Vancomycin is a crucial antibiotic for treating serious Gram-positive infections, especially those caused by MRSA. However, achieving optimal therapeutic levels can be challenging. Patients with Augmented Renal Clearance (ARC), characterized by higher-than-expected kidney function, often experience sub-therapeutic vancomycin concentrations, leading to treatment failure and the potential development of antibiotic resistance. While impaired renal function has been extensively studied for vancomycin dosing, the pharmacokinetic profile and optimal dosing strategies for patients with ARC remain less understood. This paper aims to fill that knowledge gap by developing a robust pharmacokinetic model and proposing evidence-based dosing recommendations for this specific patient population.

Methods

The researchers employed a population pharmacokinetic (PopPK) modeling approach using NONMEM 7.4.4 software. This method is standard for analyzing sparse pharmacokinetic data from a large population. They retrospectively collected 424 vancomycin serum concentrations from 209 Chinese patients.

Key methodological steps included:

  • Model Selection: Comparing one- and two-compartment models to best describe vancomycin's behavior, with the two-compartment model proving more suitable.
  • Covariate Analysis: Identifying factors that significantly influence vancomycin pharmacokinetics. Creatinine clearance (CLcr) and Intensive Care Unit (ICU) admission were found to be significant covariates for clearance (CL) and central volume of distribution (Vc), respectively.
  • Model Validation: Rigorous validation was performed using goodness-of-fit (GOF) plots, bootstrap analysis, and prediction-corrected visual predictive checks (pc-VPC) to ensure the model accurately represented the observed data.
  • Dose Optimization: Monte Carlo simulations were used to explore various dosing regimens and determine the probability of achieving target therapeutic ranges (AUC24: 400-650 mg·h/L and trough concentration: 10-20 mg/L) across different CLcr levels.

Datasets

The study utilized a retrospective dataset of 424 vancomycin serum concentrations collected from 209 hospitalized Chinese patients between January 2010 and June 2018. The dataset included patient demographics, clinical characteristics (including ICU admission, shock, and multiple organ failure), serum creatinine levels, and vancomycin serum concentrations. No new benchmarks were introduced; the study focused on analyzing existing patient data.

Key Insights and Ideas

  • ARC is a significant factor: The study strongly reinforces that ARC leads to substantially higher vancomycin clearance, necessitating dose adjustments.
  • Saturation kinetics for clearance: Unlike previous models that often assumed linear clearance, this study found that vancomycin clearance increases with CLcr but exhibits a saturation curve, meaning it doesn't increase indefinitely at very high CLcr. This is a crucial refinement for accurate dosing.
  • ICU admission dramatically impacts volume of distribution: Patients admitted to the ICU had a more than threefold increase in their central volume of distribution (Vc). This is likely due to physiological changes associated with critical illness, such as fluid shifts and increased capillary permeability.
  • Targeted AUC is key: The study emphasizes the importance of targeting the 24-hour area under the curve (AUC24) for vancomycin, as it's a better predictor of efficacy and may reduce the risk of nephrotoxicity compared to solely focusing on trough concentrations.

Key Results

  • The final population pharmacokinetic model identified creatinine clearance (CLcr) and ICU admission as significant covariates.
  • Vancomycin clearance increased with CLcr, with a theoretical maximum clearance of 5.58 L/h.
  • The central volume of distribution (Vc) was significantly higher in ICU patients (35.7 L) compared to non-ICU patients (8.02 L).
  • Monte Carlo simulations indicated that vancomycin dosage should be increased in conjunction with CLcr up to 180 mL/min to achieve target AUC24 levels.
  • Recommended initial dosage regimens were provided for various CLcr ranges, showing probabilities of target attainment (PTA) between 41% and 67%.

Limitations and Future Work

The authors acknowledge the following limitations:

  • Limited Sample Size: While 424 concentrations from 209 patients is a reasonable dataset for PopPK, a larger sample size could further refine the model and better characterize differences between ICU and non-ICU patients.
  • Covariate Limitations: While ICU admission was a significant covariate for Vc, other factors like Acute Physiology and Chronic Health Evaluation II (APACHE II) scores or other severity-of-illness indicators were not fully explored as covariates. The authors suggest that future studies could incorporate these to better understand Vc variability.

Future work suggested includes:

  • Prospective Studies: Conducting prospective studies to validate the proposed dosing regimens and assess their real-world effectiveness and safety.
  • Broader Patient Populations: Expanding the study to include a more diverse range of patient populations and geographical locations to confirm the generalizability of the findings.

Summary updated

Abstract

Patients with augmented renal clearance (ARC) have been described as having low vancomycin concentration. However, the pharmacokinetic model that best describes vancomycin in patients with ARC has not been clarified. The purpose of this study is to determine the pharmacokinetic of vancomycin in Chinese adults and the recommend dosage for patients with different renal function, including patients with ARC. We retrospectively collected 424 vancomycin serum concentrations from 209 Chinese patients and performed a population pharmacokinetic model using NONMEM 7.4.4. The final model indicated that the clearance rate of vancomycin increased together with the creatinine clearance, and exhibited a nearly saturated curve at higher creatinine clearance. The estimated clearance of vancomycin was between 3.46 and 5.58 L/h in patients with ARC, with 5.58 being the maximum theoretical value. The central volume of distribution increased by more than three times in patients admitted to Intensive Care Unit. Monte Carlo simulations were conducted to explore the probability of reaching the target therapeutic range (24-h area under the curve: 400-650 mg·h/L, trough concentration: 10-20 mg/L) when various dose regimens were administered. The simulations indicated that dose should increase together with the creatinine clearance until 180 mL/min. These findings may contribute to improving the efficacy and safety of vancomycin in patients with ARC.
BibTeX
@inproceedings{zhao2021population,
  author = {Sixuan Zhao and Na He and Yahui Zhang and Chuhui Wang and Suodi Zhai and Chao Zhang},
  title = {{Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance}},
  booktitle = {Antibiotics},
  year = {2021},
  doi = {10.3390/antibiotics10101238},
}
Figure